Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Desmopressin ODT for Nocturia in Japanese Subjects
NCT03051009Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jan 2017
- Primary completion
- Sep 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of desmopressin in nocturia (8 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: The frequency and severity of adverse events up to 1 year, Clinically significant changes in laboratory values and vital signs up to 1 year and 1 more. Started Jan 2017; status: completed.
02
Drugs
desmopressin
03
Conditions
nocturia
Beyond the preview
Go deeper on NCT03051009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051009.